ServiceTitan (NASDAQ:TTAN) Stock

SERVICETITAN INC-A

ServiceTitan

ServiceTitan Inc is an end-to-end technology platform built for contractors to transform the performance of their businesses. The Company's platform provides business owners, technicians, customer service representatives and other key office staff with technology tools designed to help customers grow revenue, drive operational efficiencies, deliver a superior end-customer experience and monitor key business drivers in real-time. The Company also has subsidiaries in Yerevan, Armenia and British Columbia, Canada that primarily serve as research and development and support centers.

ServiceTitan, Inc. - Class A Common Stock

ServiceTitan Inc

JP Morgan analyst Matthew Boss maintains Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) with a Overweight and raises the price target from $141 to $151.

News

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on Abercrombie & Fitch, Raises Price Target to $151

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.3% on Monday.
Shares of ATAI Life Sciences NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) fell sharply in pre-market trading after the company announced the Phase 2b trial of Inidascamine in patients with cognitive impairment associated with schizophrenia did not meet<a href="https://www.benzinga.com/quote/ATAI"> its primary endpoint.</a>
ATAI Life Sciences shares dipped 9.3% to $3.23 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Fusion Fuel Green PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) declined 9.2% to $6.29 in pre-market trading. Fusion Fuel Green shares jumped 47% on Friday after the company announced its subsidiary has confirmed several new projects.</li>
<li>Revvity Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NASDAQ">RVTY</a>) fell 7.4% to $96.00 in pre-market trading as the company lowered its FY2025 earnings guidance.</li>
<li>KB Financial Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KB#NYSE">KB</a>) shares declined 5.1% to $81.50 in pre-market trading after declining 5% on Friday.</li>
<li>Rapport Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPP#NASDAQ">RAPP</a>) fell 4.9% to $15.27 in pre-market trading after falling 3% on Friday.</li>
<li>Metsera Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) declined 4.9% to $38.50 in pre-market trading.</li>
<li>Volcon Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLCN#NASDAQ">VLCN</a>) fell 4.6% to $12.79 in pre-market trading.</li>
<li>Shinhan Financial Group Co Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHG#NYSE">SHG</a>) fell 4.6% to $48.59 in pre-market trading. On Friday, Shinhan Financial Group posted second-quarter earnings of $2.19 per share on sales of $2.048 billion.</li>
<li>Cantor Equity Partners I Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEPO#NASDAQ">CEPO</a>) tumbled 4.3% to $11.35 in pre-market trading.</li>
<li>Quantumscape Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) fell 3.6% to $11.54 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46655271/top-3-health-care-stocks-that-may-explode-in-july">Top 3 Health Care Stocks That May Explode In July</a></li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Movers

Trading Ideas

ATAI

CEPO

HTOO

MTSR

RAPP

RVTY

VLCN

ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Baird analyst Catherine Schulte maintains Avantor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) with a Outperform and raises the price target from $17 to $18.

AVTR

Baird Maintains Outperform on Avantor, Raises Price Target to $18

CTSH

LINE

Cognizant Technology Solutions Partners With Lineage For Customer Service Transformation

GFAI

Guardforce AI Launches Smart Solutions And AI Applications At Rebranding Event Hosted By Thai Subsidiary, Guardforce Cash Solutions Security In Bangkok

Baird analyst Timothy Wojs maintains Mohawk Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>) with a Outperform and raises the price target from $130 to $142.

Baird Maintains Outperform on Mohawk Industries, Raises Price Target to $142

Upon the closing of the Private Placement, Mill City will adopt a Sui Treasury Strategy
Mill City intends to continue its short-term non-bank lending and specialty finance business
Marius Barnett and Stephen Mackintosh, Co-founders of Karatage, will become Chairman of the Board of Directors of the Company and Chief Investment Officer of the Company, respectively, effective upon the closing of the Private Placement
Industry-First Relationship with Sui Foundation Provides Institutional-Grade Gateway for Exposure to Only Blockchain Built for Mass Adoption
Mill City Ventures III, Ltd. ("Mill City" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCVT#NASDAQ">MCVT</a>), a non-bank lender and specialty finance company, today announced that it has entered into securities purchase agreements (the "Securities Purchase Agreements") for a private investment in public equity for the purchase and sale of 83,025,830 shares of common stock (or common stock equivalents in lieu thereof) at a price of $5.42 per share for expected aggregate gross proceeds of approximately $ 450,000,000, before deducting placement agent fees and other offering expenses (the "Private Placement", or the "Offering").
Karatage Opportunities ("Karatage"), the London-based proprietary hedge fund specializing in digital assets and emerging technology investments, founded by Marius Barnett and Stephen Mackintosh, acted as the lead investor, with an equivalent investment from the Sui Foundation, an independent organization dedicated to the advancement and adoption of the Sui network. As a significant early investor in the Sui ecosystem, Karatage has established itself as a strategic partner to Mysten Labs, the original contributors to Sui, with deep operational experience across the Sui network.
The Offering included participation by prominent firms and infrastructure providers Big Brain Holdings, Galaxy Digital Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLXY#NASDAQ">GLXY</a>) and Dr Jack Kong – NLABS Fund as well as investment from Pantera Capital , M2, Electric Capital, GSR, Selini, Protagonist, ParaFi Capital, Borderless, dao5, Arrington Capital, Comma3 Ventures, FalconX, Paper Ventures and Maven 11 amongst others. Galaxy Asset Management will serve as the Asset Manager.
The closing of the Offering is expected to occur on or about July 31, 2025, subject to the satisfaction of customary closing conditions. The Company intends to use approximately 98% of the net proceeds from the Private Placement to acquire the native cryptocurrency of the Sui blockchain commonly referred to as "SUI", and approximately 2% of the net proceeds from the Private Placement to fund the Company's short-term lending business. SUI will serve as the Company's primary treasury reserve asset.
A.G.P./Alliance Global Partners is acting as the sole placement agent in connection with the offering.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Offerings

GLXY

MCVT

Mill City Ventures Announces $450M Private Placement Of 83M Shares At $5.42/Share; Will Adopt Sui Treasury Strategy, Invest 98% In SUI Token

Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) will release earnings results for the second quarter before the opening <a href="https://www.benzinga.com/quote/MRK/earnings">bell on Tuesday, July 29.</a>
Analysts expect the health care company to report quarterly earnings at $2.03 per share, down from $2.28 per share in the year-ago period. Merck projects to report quarterly revenue at $15.87 billion, compared to $16.11 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
With the recent buzz around Merck, some investors may be eyeing potential gains from the company's dividends. Merck offers an annual dividend yield of 3.82% — a quarterly dividend amount of 81 cents per share ($3.24 a year).
To figure out how to earn $500 monthly from Merck, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Merck's $3.24 dividend: $6,000 / $3.24 = 1,852 shares.
So, an investor would need to own approximately $156,883 worth of Merck, or 1,852 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $3.24 = 370 shares, or $31,343 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis; the dividend payment and the stock price fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
MRK Price Action: Shares of Merck rose by 0.7% to close at $84.71 on Friday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46628925/top-2-materials-stocks-that-may-fall-off-a-cliff-this-month">Top 2 Materials Stocks That May Fall Off A Cliff This Month</a></li>
</ul>
Image: Shutterstock

Earnings

Long Ideas

Dividends

How To Earn $500 A Month From Merck Stock Ahead Of Q2 Earnings

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.chargepoint.com%2F&amp;esheet=54297266&amp;newsitemid=20250727351893&amp;lan=en-US&amp;anchor=ChargePoint&amp;index=1&amp;md5=d2bf6c9ef6d93e86152f2ae96ddff240">ChargePoint</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>), a leading provider of EV charging solutions, announced that today the Company implemented a reverse stock split of its common stock at a ratio of 1-for-20, which will be reflected at market open. The reverse stock split is intended to increase the market price per share of the Company's common stock and help the Company comply with the minimum trading price criteria for continued listing on the New York Stock Exchange (the "NYSE").
On July 8, 2025, ChargePoint shareholders approved a reverse stock split ratio within a range of 1-for-2 to 1-for-30 at the Company's 2025 Annual Meeting of Stockholders (the "Annual Meeting") and authorized the Company's Nominating and Corporate Governance Committee to determine and execute the final ratio. The Company's Nominating and Corporate Governance Committee subsequently approved the final reverse split ratio of 1-for-20.
The reverse stock split will not modify any rights or preferences of the Company's common stock. The trading symbol for the Company's common stock will remain "CHPT." The new CUSIP number for the Company's common stock following the reverse stock split will be 15961R 303 and the new ISIN number will be US15961R3030.
Effective as of 12:01 am Eastern Time today, July 28, 2025, every twenty (20) issued and outstanding shares of the Company's common stock have been converted into one share of the Company's common stock.
The reverse stock split will affect all shareholders uniformly and will not affect any shareholder's percentage ownership interest in the Company (except to the extent that the reverse stock split would result in any of the shareholders owning a fractional interest). Shareholders who otherwise would be entitled to receive fractional shares will receive a cash payment in lieu of such fractional shares.
Stockholders who hold their shares in "street name" that is through a brokerage firm, bank, dealer or other similar organization, will have their positions automatically adjusted to reflect the reverse stock split, subject to each broker's particular processes, and do not need to take any action in connection with the reverse stock split. Stockholders of record will be receiving information from Continental Stock Transfer &amp; Trust Company, the Company's transfer agent, regarding their stock ownership following the reverse stock split.
Additional information regarding the reverse stock split and other matters voted on at the Annual Meeting can be found in the Form 8-K filed with the U.S. Securities and Exchange Commission on July 9, 2025, and on ChargePoint's Investor Relations website at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.chargepoint.com%2Foverview%2Fdefault.aspx&amp;esheet=54297266&amp;newsitemid=20250727351893&amp;lan=en-US&amp;anchor=investors.chargepoint.com&amp;index=2&amp;md5=61afe99c5a40371d9d5df64dff07a22c">investors.chargepoint.com</a>.
&nbsp;

Stock Split

CHPT

ChargePoint Announces 1-For-20 Reverse Stock Split, Effective July 28, 2025

Baird analyst Michael Bellisario maintains Hyatt Hotels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) with a Neutral and raises the price target from $148 to $150.

Baird Maintains Neutral on Hyatt Hotels, Raises Price Target to $150

D. Boral Capital analyst Jason Kolbert maintains CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) with a Buy and maintains $10 price target.

CRVO

D. Boral Capital Maintains Buy on CervoMed, Maintains $10 Price Target

180 Degree Capital Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TURN#NASDAQ">TURN</a>) ("180 Degree Capital") today noted the recent announcement by its portfolio company, Synchronoss Technologies, Inc. ("SNCR"), that stated SNCR received $30.2 million of its $33.9 million tax refund, and that SNCR expects the remaining $3.7 million to be received prior to Labor Day 2025. SNCR noted in its press release that:

TURN

180 Degree Capital Announces Portfolio Company Synchronoss Technologies Received $30.2M Tax Refund, With Remaining $3.7M Expected By Labor Day 2025

Southern Calif Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAL#NASDAQ">BCAL</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.41 by 5.65 percent. This is a 104.76 percent increase over earnings of $0.21 per share from the same period last year. The company reported quarterly sales of $44.273 million which missed the analyst consensus estimate of $44.786 million by 1.15 percent. This is a 99.64 percent increase over sales of $22.176 million the same period last year.

Earnings Beats

Earnings Misses

BCAL

Southern Calif Bancorp Q2 EPS $0.43 Beats $0.41 Estimate, Sales $44.273M Miss $44.786M Estimate

- Radiopharm Theranostics (ASX: RAD, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has provided clearance of the Company's Investigational New Drug (IND) application for Betabart (RV-01), its Lu177-B7H3 monoclonal antibody designed with strong affinity for the 4Ig isoform of B7H3 that is highly expressed in tumors and not in healthy tissues.
"FDA clearance to initiate our first-in-human Phase 1 clinical trial of RV-01 represents a major milestone for Radiopharm Theranostics and our joint venture with MD Anderson Cancer Center," said Riccardo Canevari, CEO and Managing Director. "RV-01 is the first monoclonal antibody developed through this collaboration, and we believe it has the potential to become a highly differentiated radiopharmaceutical for patients with aggressive solid tumors. We are excited to advance this program into the clinic and anticipate dosing the first patients later this year."
"Recent reported preclinical studies demonstrated that RV-01 exhibits hepatic clearance, allowing the isotope sufficient time to effectively target tumors while potentially minimizing adverse effects such as hematological toxicities. Unlike peptides or small molecules, monoclonal antibodies are primarily cleared by the liver—an organ known for its radio-resistance. This characteristic, combined with the shortened half-life of RV-01 and the strong affinity for the target make this agent stand out and may offer a significant advantage not just over other monoclonal antibodies but also targeted radiotherapeutics with renal excretion pathway, the latter of which are often associated with higher risk of radiopharmaceutical-induced kidney toxicity," noted Dimitris Voliotis, M.D., Chief Medical Officer of Radiopharm Theranostics.
"The high affinity and selectivity of RV-01 for the 4Ig isoform of B7H3 allows the antibody to bypass the soluble 2Ig isoform in the blood,&nbsp;boost binding of the radiopharmaceutical to tumor targets and avoid the formation of immune complexes in circulation," noted David Piwnica-Worms, M.D., Ph.D., Professor, MD Anderson Cancer Center, and scientific co-founder of Radiopharm Ventures.
B7-H3 is an immune checkpoint molecule that is overexpressed across several tumor types and has emerged as a compelling target for antibody-based cancer immunotherapy. Deregulated B7-H3 expression is consistently correlated with enhanced tumor aggressiveness and poor clinical outcomes. Targeting the 4 Ig isoform of B7-H3 with a selective radioligand therapy may offer a novel strategy for treating refractory or high-risk tumors.

Biotech

General

RADX

Radiopharm Theranostics Announces That The U.S. FDA Has Cleared Its Investigational New Drug Application For Betabart , A Monoclonal Antibody Targeting The 4Ig Isoform Of B7h3, Which Is Highly Expressed In Tumors But Not In Healthy Tissues

Holdco Asset Management Issued Presentation To Comerica Detailing Concerns And Requesting Immediate Sale Process

Sierra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSRR#NASDAQ">BSRR</a>) reported quarterly earnings of $0.78 per share which beat the analyst consensus estimate of $0.74 by 5.69 percent. This is a 9.86 percent increase over earnings of $0.71 per share from the same period last year. The company reported quarterly sales of $39.206 million which beat the analyst consensus estimate of $38.523 million by 1.77 percent. This is a 3.72 percent increase over sales of $37.800 million the same period last year.

BSRR

Sierra Q2 EPS $0.78 Beats $0.74 Estimate, Sales $39.206M Beat $38.523M Estimate

<h3>Gainers</h3>
<ul>
<li>Volcon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLCN#NASDAQ">VLCN</a>) shares rose 29.4% to $17.34 during Monday's pre-market session. The market value of their outstanding shares is at $602.4 million. </li>
<li>Majestic Ideal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MJID#NASDAQ">MJID</a>) shares moved upwards by 20.44% to $2.18. The market value of their outstanding shares is at $37.1 million. </li>
<li>Kirkland's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIRK#NASDAQ">KIRK</a>) stock rose 19.59% to $1.78. The company's market cap stands at $33.4 million. </li>
<li>YSX Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YSXT#NASDAQ">YSXT</a>) stock moved upwards by 11.62% to $4.61. The market value of their outstanding shares is at $96.7 million. </li>
<li>Tron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRON#NASDAQ">TRON</a>) shares rose 11.25% to $10.68. The company's market cap stands at $171.2 million. </li>
<li>ZSPACE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZSPC#NASDAQ">ZSPC</a>) stock rose 10.63% to $3.33. The market value of their outstanding shares is at $68.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Fly-E Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYE#NASDAQ">FLYE</a>) shares declined by 7.1% to $5.01 during Monday's pre-market session. The market value of their outstanding shares is at $97.5 million. </li>
<li>Jiuzi Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZXN#NASDAQ">JZXN</a>) stock declined by 4.08% to $1.06. The market value of their outstanding shares is at $12.1 million. </li>
<li>LightInTheBox Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LITB#NYSE">LITB</a>) stock decreased by 4.01% to $1.2. The market value of their outstanding shares is at $22.8 million. </li>
<li>REE Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REE#NASDAQ">REE</a>) stock decreased by 3.76% to $0.73. The company's market cap stands at $21.3 million. </li>
<li>Golden Heaven Group Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) stock fell 3.56% to $0.52. The company's market cap stands at $20.5 million. </li>
<li>QuantumScape (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) stock decreased by 3.51% to $11.55. The market value of their outstanding shares is at $6.6 billion. As per the news, the Q2 earnings report came out 3 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FLYE

GDHG

JZXN

KIRK

LITB

MJID

TRON

YSXT

ZSPC

12 Consumer Discretionary Stocks Moving In Monday's Pre-Market Session

UroGen Pharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>), a biotech company dedicated to developing and commercializing innovative treatments for urothelial and specialty cancers, today announced the publication in Reviews in Urology of results from a Phase 3b study evaluating the feasibility of administering ZUSDURI&#x2122; (mitomycin) for intravesical solution (formerly known as UGN-102) in the home setting. The study, titled "Home Instillation of UGN-102 for Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Single-Arm, Open-Label, Phase 3b Trial," demonstrated that trained home health professionals (HHPs) can safely and effectively administer ZUSDURI outside of a traditional clinical setting.
The study assessed the feasibility, safety, and early efficacy of at-home instillations of ZUSDURI in patients with recurrent LG-IR-NMIBC. Six of eight patients (75%) completed all six scheduled treatments, with five of those six patients indicating they would recommend the home-based approach to others. A 75% complete response (CR) rate was observed at three months (95% CI: 34.9, 96.8), and no new safety concerns were identified. Feasibility questionnaires were completed by patients, and HHPs throughout the study. After each home instillation, patients rated their experience based on comfort, safety, communication, preference compared to office instillation, and overall satisfaction. At study end, they were also asked whether they would recommend home instillation of ZUSDURI to other patients and as an alternative to undergoing TURBT. Investigators assessed the clinical comparability of home versus in-office administration. HHPs provided feedback after each visit and at the study's conclusion, reporting on their comfort with the procedure, perceived difficulty, and adequacy of training and support.
In this study, ZUSDURI was administered via urinary catheter once weekly for six weeks, with the first dose administered in the clinic, followed by five at-home instillations by HHPs. Investigators found no meaningful differences between home and office instillation for most patients. The safety profile was consistent with previous studies, with most adverse events being mild-to-moderate urinary symptoms.
Study limitations include, among others, the small sample size of eight patients, and the open-label and single-arm design.

URGN

UroGen Pharma Announces Publication In Reviews In Urology Of Results From Phase 3b Study Evaluating Feasibility Of Administering ZUSDURI For Intravesical Solution In Home Setting

<h3>Gainers</h3>
<ul>
<li>Celcuity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) stock rose 241.8% to $47.06 during Monday's pre-market session. The market value of their outstanding shares is at $521.4 million. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) stock rose 41.31% to $12.69. The company's market cap stands at $78.1 million. </li>
<li>Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) stock increased by 17.73% to $2.39. The company's market cap stands at $187.0 million. </li>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares moved upwards by 17.69% to $3.48. The company's market cap stands at $70.8 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) stock moved upwards by 17.31% to $0.37. The company's market cap stands at $19.1 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock increased by 17.22% to $0.08. The market value of their outstanding shares is at $27.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) stock decreased by 36.6% to $0.22 during Monday's pre-market session. The market value of their outstanding shares is at $91.9 million. </li>
<li>Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) shares fell 16.04% to $5.5. The company's market cap stands at $96.9 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) shares fell 13.34% to $2.6. The market value of their outstanding shares is at $18.1 million. As per the press release, Q2 earnings came out 3 days ago. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) stock fell 11.4% to $0.65. The market value of their outstanding shares is at $25.2 million. </li>
<li>Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) shares fell 9.19% to $1.64. The company's market cap stands at $36.4 million. </li>
<li>Revvity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>) shares fell 7.4% to $96.0. The company's market cap stands at $12.2 billion. As per the press release, Q2 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADAP

Alterity Therapeutics Limited - American Depositary Shares

ATHE

ATNF

CAMP

CELC

CELU

CLDI

HCTI

IPHA

12 Health Care Stocks Moving In Monday's Pre-Market Session

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Ascendiant Capital analyst Edward Woo initiated coverage on Alarum Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>) with a Buy rating and announced a price target of $9. Allarity Therapeutics shares closed at $12.23 on Friday. <a href="https://www.benzinga.com/quote/ALLR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst Keith Bachman initiated coverage on MongoDB, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with an Outperform rating and announced a price target of $280. MongoDB shares closed at $241.37 on Friday. <a href="https://www.benzinga.com/quote/MDB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HSBC analyst Phani Kanumuri initiates coverage on Accenture plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) with a Reduce rating and announced a price target of $240. Accenture shares closed at $283.15 on Friday. <a href="https://www.benzinga.com/quote/ACN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer analyst Cheng Li initiated coverage on Wave Life Sciences Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with an Outperform rating and announced a price target of $24. WAVE Life Sciences shares closed at $8.40 on Friday. <a href="https://www.benzinga.com/quote/WVE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Alec Brondolo initiated coverage on Take-Two Interactive Software, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) with an Overweight rating and announced a price target of $265. Take-Two Interactive shares closed at $224.75 on Friday. <a href="https://www.benzinga.com/quote/TTWO/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying MDB stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="571" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28080652/image-426-1024x571.png" alt="" class="wp-image-1003169" style="width:614px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28080652/image-426-1024x571.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28080652/image-426-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28080652/image-426-768x428.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28080652/image-426.png 1123w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46655271/top-3-health-care-stocks-that-may-explode-in-july">Top 3 Health Care Stocks That May Explode In July</a></li>
</ul>
Photo via Shutterstock

Initiation

ALLR

TTWO

This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Press Releases

ServiceTitan to Announce Fiscal First Quarter 2026 Financial Results on June 5, 2025

ServiceTitan Announces Fiscal First Quarter Financial Results

ServiceTitan Partners with EagleView to Empower Roofing and Exterior Contractors

ServiceTitan Announces Integration with ABC Supply Co., Empowering Roofing and Exterior Contractors to Improve Efficiency and Profitability

ServiceTitan Achieves 'Built for NetSuite' Status

ServiceTitan Partners with Associated Builders and Contractors to Empower Construction Professionals

ServiceTitan and Pine Services Group Partner to Deliver Comprehensive Solutions for Commercial and Construction Industries

New FieldRoutes Data Finds Software is Key to Profit Growth as Pest Industry Faces Rising Costs

ServiceTitan to Host Investor Session at Pantheon 2025

Majority of Contractors Report Stable or Rising Revenue in ServiceTitan's 2025 Commercial Service Market Survey

Comments

ServiceTitan

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL